Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$27.68 ▲ +0.40
(+1.47%)
MKT CAP: $229.4M • VOL: 26.9K
52W L $23 52W H $47
ELMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $64.0M | $54.7M | $48.1M |
| YoY Revenue Growth % | +17.0% | +13.8% | — |
| Gross Profit | $50.0M | $41.7M | — |
| Gross Margin % | 78.1% | 76.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $9.7M | $6.6M | $4.0M |
| Operating Margin % | 15.1% | 12.0% | 8.3% |
| Net Income (GAAP) | $7.5M | $5.2M | $3.2M |
| EBITDA (Normalized) | $9.9M | $6.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $11.4M | $9.1M | $1.3M |
| Capital Expenditures (CapEx) | $262.0K | $287.0K | — |
| Free Cash Flow (FCF) | $11.1M | $8.8M | $1.3M |
| FCF Margin % | 17.4% | 16.0% | 2.7% |
| Return on Invested Capital (ROIC %) | 24.1% | 19.0% | — |
| Cash & Short-Term Equivalents | $13.8M | $16.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $45.4M | $43.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ELMD.